Edgewise Therapeutics (EWTX) Accumulated Expenses (2020 - 2026)

Edgewise Therapeutics has reported Accumulated Expenses for 7 years, with the latest figure at $8.6 million in Q1 2026.

• Quarterly Accumulated Expenses rose 115.27% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (up 115.27% YoY) and the FY2025 annual result came in at $7.9 million, up 9.56% from the prior year.
• Accumulated Expenses climbed to $8.6 million in Q1 2026 per EWTX's latest filing, from $7.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $8.6 million in Q1 2026 and troughed at $1.3 million in Q1 2022.
• A 5-year average of $5.4 million and a median of $5.8 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 343.46% in 2023, then slumped 51.01% in 2024.
• Over 5 years, Accumulated Expenses stood at $5.8 million in 2022, then increased by 3.96% to $6.1 million in 2023, then gained by 19.07% to $7.2 million in 2024, then gained by 9.56% to $7.9 million in 2025, then climbed by 8.02% to $8.6 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $8.6 million, $7.9 million, and $6.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.